Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

Witjes, 2021, EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer Karakiewicz, 2006, Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder, BJU Int, 10.1111/j.1464-410X.2006.06036.x Lee, 2020, Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer : Results of Two Systematic Literature Reviews, Clin Outcomes Res, 693, 10.2147/CEOR.S274951 Soria, 2018, An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer, World J Urol, 36, 1981, 10.1007/s00345-018-2380-x Chang, 2016, Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline, J Urol, 196, 1021, 10.1016/j.juro.2016.06.049 Wolfs, 2021, Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review, Urol Oncol Semin Orig Investig, 39, 161 Shim, 2019, Diagnostic test accuracy: application and practice using R software, Epidemiol Health Leeflang, 2008, Systematic reviews of diagnostic test accuracy, Ann Intern Med, 149, 889, 10.7326/0003-4819-149-12-200812160-00008 McInnes, 2018, Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement, JAMA, 319, 388, 10.1001/jama.2017.19163 Whiting, 2011, Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 10.7326/0003-4819-155-8-201110180-00009 Reitsma, 2005, Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews, J Clin Epidemiol, 58, 982, 10.1016/j.jclinepi.2005.02.022 Shim, 2019, Network meta-analysis: application and practice using the R software, Epidemiol Health, 41 Spiegelhalter, 2002, Bayesian measures of model complexity and fit, J R Stat Soc Ser B Stat Methodol, 64, 583, 10.1111/1467-9868.00353 Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparisons, Stat Med, 23, 3105, 10.1002/sim.1875 Salanti, 2011, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial, J Clin Epidemiol, 10.1016/j.jclinepi.2010.03.016 Rücker, 2015, Ranking treatments in frequentist network meta-analysis works without resampling methods, BMC Med Res Methodol, 10.1186/s12874-015-0060-8 Cancel-Tassin, 2021, Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up, World J Urol, 10.1007/s00345-021-03629-1 Cowan, 2021, Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients, BJU Int, 10.1111/bju.15418 Elsawy, 2021, Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer, Urol Oncol, 39, 77.e9, 10.1016/j.urolonc.2020.07.013 Elsawy, 2021, Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker, Urol Oncol Semin Orig Investig D’Elia, 2021, Diagnostic value of Xpert ® Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer : an update, Ther Adv Urol, 1 Hurle, 2020, Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA - based urine test, in active surveillance (AS) patients with recurrent non - muscle - invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance, World J Urol, 38, 2215, 10.1007/s00345-019-03002-3 Pichler, 2018, Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance, BJU Int, 121, 29, 10.1111/bju.14019 Smrkolj, 2021, The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors, Radiol Oncol Van, 2018, Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer, Eur Urol, 75, 853 Trenti, 2020, Comparison of 2 New Real-Time Polymerase Chain Reaction – Based Urinary Markers in the Follow-Up of Patients With Non – Muscle-Invasive Bladder Cancer, Cancer Cytopathol, 341, 10.1002/cncy.22246 D’Andrea, 2019, Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer, BJU Int, 123, 959, 10.1111/bju.14673 Pierconti, 2021, The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?, Urol Oncol Semin Orig Investig, 39, 131.e17 Trenti, 2019, Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non–muscle-invasive bladder cancer, Cancer Cytopathol, 127, 465, 10.1002/cncy.22152 Wasserstrom, 2016, Mp13-15 Molecular Urine Cytology – Bladder Epicheck Is a Novel Molecular Diagnostic Tool for Monitoring of Bladder Cancer Patients, J Urol, 195, 10.1016/j.juro.2016.02.2496 Roupret, 2020, Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study, J Urol, 204, 685, 10.1097/JU.0000000000001084 Białek, 2021, MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study, Cancer Biomarkers, 30, 139, 10.3233/CBM-200316 Gontero, 2021, Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study, BJU Int, 127, 198, 10.1111/bju.15194 Batista, 2019, Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study, Front Genet, 10, 1, 10.3389/fgene.2019.01237 Sieverink, 2020, Clinical validation of a urine test (uromonitor-V2®) for the surveillance of non-muscle-invasive bladder cancer patients, Diagnostics, 10, 10.3390/diagnostics10100745 Koya, 2020, An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer, BMC Urol, 20, 1, 10.1186/s12894-020-0583-0 Lotan, 2017, Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma, Urol Oncol Semin Orig Investig, 35, 531.e15 Ritch, 2020, Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort, J Urol, 203, 05, 10.1097/JU.0000000000000593 Van Valenberg, 2020, Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria, Eur Urol Oncol, 4, 93, 10.1016/j.euo.2020.09.001 Wallace, 2018, Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection, J Urol, 199, 655, 10.1016/j.juro.2017.09.141 Anastasi, 2020, Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study, Diagn Cytopathol, 48, 1034, 10.1002/dc.24530 Dudderidge, 2019, A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria—A Prospective Multicentre Performance Evaluation of ADXBLADDER, Eur Urol Oncol, 3, 42, 10.1016/j.euo.2019.06.006 O’Sullivan, 2012, A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria, J Urol, 188, 741, 10.1016/j.juro.2012.05.003 Davidson, 2019, Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy, N Z Med J, 132, 55 Fu, 2016, Nuclear matrix protein 22 (NMP22) test in the diagnosis of bladder cancer: A meta-analysis, Int J Clin Exp Med, 9, 7965 hou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. A Systematic Review and Meta-analysis Annals of Internal Medicine Urinary Biomarkers for Diagnosis of Bladder Cancer 2015. https://doi.org/10.7326/M15-0997. Leal, 2016, Economic Burden of Bladder Cancer Across the European Union, Eur Urol, 69, 438, 10.1016/j.eururo.2015.10.024 Lotan, 2021, Alternating Cystoscopy with Bladder EpiCheck ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model, Bl Cancer, 1 Han, 2019, Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-Muscle-invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors, Urology, 112, 10.1016/j.urology.2019.04.036 Brummelhuis, 2018, The conundrum of recurrent low-grade tumours: To treat or to observe?, Curr Opin Urol, 28, 557, 10.1097/MOU.0000000000000550 Contieri, 2021, Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience, Eur Urol Oncol, 10.1016/j.euo.2021.05.002 Benderska-Söder, 2020, Toward noninvasive follow-up of low-risk bladder cancer – Rationale and concept of the UroFollow trial*, Urol Oncol Semin Orig Investig, 38, 886 Konety, 2019, Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy(Figure presented.), Eur Urol, 76, 238, 10.1016/j.eururo.2019.04.035 Bensalah, 2007, Challenges of Cancer Biomarker Profiling, Eur Urol, 10.1016/j.eururo.2007.09.036 Woldu, 2021, Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence, Urol Oncol Semin Orig Investig Bellmunt, 2021, Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 22, 525, 10.1016/S1470-2045(21)00004-8 Khadhouri, 2021, The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study, BJU Int, 10.1111/bju.15483